Beech Hill Advisors Inc. Grows Position in Kenvue Inc. (NYSE:KVUE)

Beech Hill Advisors Inc. raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 106,881 shares of the company’s stock after acquiring an additional 987 shares during the period. Beech Hill Advisors Inc.’s holdings in Kenvue were worth $2,282,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Leo Wealth LLC lifted its stake in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares in the last quarter. Alerus Financial NA grew its stake in shares of Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after buying an additional 491 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares during the period. Wolff Wiese Magana LLC lifted its position in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Finally, Marathon Capital Management boosted its holdings in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after acquiring an additional 514 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE traded down $0.01 during midday trading on Thursday, reaching $20.84. The company’s stock had a trading volume of 336,338 shares, compared to its average volume of 8,273,496. The company has a market cap of $39.96 billion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average price of $22.50 and a 200 day moving average price of $21.64.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on KVUE shares. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus target price of $23.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.